Epigenomics Q1 Revenues Rise 15 Percent as it Awaits FDA, CFDA Decisions | GenomeWeb

NEW YORK (GenomeWeb) – Epigenomics today reported a 15 percent year-over-year increase in its first quarter revenues as product revenues were up 32 percent.

The German-American molecular diagnostics company said that for the three months ended March 31, revenues rose to €407,000 ($559,000) from €355,000. Product revenues increased to €215,000 from €163,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.